Skip to main content

Table 2 relationship between expression of mir-1307-5p and clinicopathological factors

From: MiR-1307-5p targeting TRAF3 upregulates the MAPK/NF-κB pathway and promotes lung adenocarcinoma proliferation

Pathological parameters n Expression level of mir-1307-5p
high expression Low expression P
Age
 <55 28 18 (30.5%) 10 (32.3%)  
     0.524
 ≥ 55 62 41 (69.5%) 21 (67.7%)  
Gender     
 Male 46 34 (57.6%) 12 (38.7%)  
     0.069
 Female 44 25 (42.4%) 19 (61.3%)  
Pathological stage
 I 15 10 (16.9%) 5 (16.1%)  
 II 55 36 (61.0%) 19 (61.3%) 0.994
 III 20 13 (22.0%) 7 (22.6%)  
TNM staging
 T     
 T1 65 47 (79.7%) 18 (58.1%)  
 T2 21 11 (18.6%) 10 (32.3%)  
     0.027
 T3 3 0 (0.0%) 3 (9.7%)  
 T4 1 1 (1.7%) 0 (0.0%)  
 N     
 N0 56 36 (61.0%) 20 (64.5%)  
 N1 21 15 (25.4%) 6 (19.4%)  
     0.797
 N2 13 8 (13.6%) 5 (16.1%)  
 N3 0 0 (0.0%) 0 (0.0%)  
 M     
 M0 90 43 (72.9%) 22 (71.0%)  
     0.517
 M1 2 16 (27.1%) 9 (29.0%)  
Clinical stages     
 I 40 25 (42.4%) 15 (48.4%)  
 II 19 15 (25.4%) 4 (12.9%)  
     0.504
 III 6 3 (5.1%) 3 (9.7%)  
 IV 25 16 (27.1%) 9 (29.0%)